1. Home
  2. PNTG vs OMER Comparison

PNTG vs OMER Comparison

Compare PNTG & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Pennant Group Inc.

PNTG

The Pennant Group Inc.

HOLD

Current Price

$29.09

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$11.90

Market Cap

894.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PNTG
OMER
Founded
2019
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
894.8M
IPO Year
N/A
2009

Fundamental Metrics

Financial Performance
Metric
PNTG
OMER
Price
$29.09
$11.90
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
5
Target Price
$36.50
$32.50
AVG Volume (30 Days)
198.0K
4.4M
Earning Date
02-26-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
10.47
N/A
EPS
0.75
N/A
Revenue
$847,274,000.00
N/A
Revenue This Year
$36.42
N/A
Revenue Next Year
$23.99
N/A
P/E Ratio
$39.77
N/A
Revenue Growth
29.89
N/A
52 Week Low
$21.18
$2.95
52 Week High
$30.46
$17.65

Technical Indicators

Market Signals
Indicator
PNTG
OMER
Relative Strength Index (RSI) 52.83 47.41
Support Level $28.21 $11.85
Resistance Level $29.00 $13.26
Average True Range (ATR) 0.91 1.32
MACD -0.02 -0.46
Stochastic Oscillator 55.06 4.22

Price Performance

Historical Comparison
PNTG
OMER

About PNTG The Pennant Group Inc.

Pennant Group Inc is engaged in providing healthcare services to patients of all ages, including the growing senior population, in the United States. It operates in multiple lines of business including home health, hospice, and senior living which includes the company's assisted living, independent living, and memory care communities across Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The company generates majority of its revenue from home health and hospice services segment, which includes its home health, hospice and home care businesses.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: